Only Available By Prescription
Sign up to get notified if we do in the future.
We guarantee the lowest price on all of our prescription products. If you find your medications cheaper at any other recognized licensed mail order pharmacy, we will not only match their price, we will beat it by 25% of the difference. It is our 125% price match guarantee!
Example: If you find a product on Canada Drugs Direct for $50.00 and find the same product for $40.00 at another mail order pharmacy, we will provide you with a $12.50 discount, bringing your total to $37.50.
To get the discount please make sure to mention the price match to the customer service team when they call to collect payment for your order. Or call toll free at 1-888-904-8467 to place the order through the phone.
Terms & Conditions of Program
A generic drug is a copy of the brand-name drug with the same dosage, safety, strength, quality, consumption method, performance, and intended use. Before generics become available on the market, the generic company must prove it has the same active ingredients as the brand-name drug and works in the same way and in the same amount of time in the body.
The only differences between generics and their brand-name counterparts is that generics are less expensive and may look slightly different (eg. different shape or color), as trademarks laws prevent a generic from looking exactly like the brand-name drug.
Generics are less expensive because generic manufacturers don't have to invest large sums of money to develop a drug. When the brand-name patent expires, generic companies can manufacture a copy of the brand-name and sell it at a substantial discount.
Yuflyma (adalimumab-aaty) is a biosimilar to Humira (adalimumab), a fully human monoclonal antibody that targets tumor necrosis factor-alpha (TNF-a). It is indicated for the treatment of multiple chronic inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, hidradenitis suppurativa, plaque psoriasis, juvenile idiopathic arthritis, and uveitis. Yuflyma binds specifically to TNF-a, neutralizing its activity and reducing inflammation, tissue destruction, and immune dysregulation associated with autoimmune diseases.
| Fact Table | |
| Formula | C6428H9912N1694O1987S46 |
| License | US FDA (biosimilar approved in 2023) |
| Bioavailability | 64% (subcutaneous) |
| Legal status | Prescription only (Rx-only) |
| Chemical Name | Adalimumab |
| Elimination half-life | 10–20 days |
| Dosage (Strength) | 40 mg/0.4 mL, 40 mg/0.8 mL prefilled syringe or pen (subcutaneous) |
| Pregnancy | Consult a doctor (Category B) |
| Brands | Yuflyma (biosimilar), Humira (reference product) |
| Protein binding | Not applicable (monoclonal antibody) |
| PubChem CID | 11503014 |
| MedlinePlus | a603010 |
| ChEBI | 131722 |
| ATC code | L04AB04 |
| DrugBank | DB00051 |
| KEGG | D03136 |
| Routes of administration | Subcutaneous |
Yuflyma is administered as a subcutaneous injection. The dosage and frequency depend on the indication and patient factors such as age and body weight. For example, in adult rheumatoid arthritis, the typical dose is 40 mg every other week, which may be increased to weekly administration if needed. Pediatric dosages vary based on weight and indication.
The injection should be given in the thigh or abdomen, rotating injection sites with each dose. Patients may self-administer after proper training by a healthcare professional. The product should be stored refrigerated and brought to room temperature before use.
Each prefilled syringe or autoinjector of Yuflyma contains 40 mg of adalimumab-aaty in 0.4 mL solution (100 mg/mL). Inactive ingredients include histidine, histidine hydrochloride monohydrate, trehalose dihydrate, polysorbate 80, and water for injection. Yuflyma is latex-free and citrate-free, formulated to reduce injection site pain.
Yuflyma is contraindicated in patients with known hypersensitivity to adalimumab or any excipients. It is also contraindicated in patients with active tuberculosis or other severe infections such as sepsis, and in those with moderate to severe heart failure (NYHA Class III/IV).
Serious infections, including tuberculosis, invasive fungal infections, and opportunistic pathogens, have occurred. Patients should be evaluated for TB risk and screened for latent tuberculosis prior to initiation. Reactivation of hepatitis B has also been reported. Use caution in patients with chronic or recurrent infections, demyelinating diseases, malignancies, or those on concurrent immunosuppressive therapy.
Patients should be monitored for new or worsening neurological symptoms, signs of malignancy (particularly lymphoma in pediatric and adolescent patients), and hematologic abnormalities. Live vaccines should be avoided during treatment.
Common and serious side effects associated with Yuflyma include:
Exceptional Customer Service
We pride ourselves on delivering excellent customer service with as much accessibility as possible.
If you have any questions at all, or would like to place an order, you are encouraged to contact us by toll-free
phone 1-888-904-8467 or email info@canadadrugsdirect.com.
Top Safety and Quality
Canada Drugs Direct employs dedicated, professional licensed pharmacists to ensure that each and every order is reviewed before it is dispensed for the safety and health of our customers. At CanadaDrugsDirect.com, your health is our top priority.
Product Reviews